• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Bayer and Nuvisan Create New Research Unit in Berlin


Bayer (Leverkusen, Germany) announced it has entered into a definitive agreement to transfer a large part of its Berlin-based small molecule research unit to Nuvisan, an international service provider for clinical studies, laboratory services and contract manufacturing with several sites and clinics in Germany and France. The strategic partnership will lay the foundation for a new research entity to be established by Nuvisan in Berlin. At the same time, it will support Bayer’s increased focus on the flexibility and productivity of its R&D operating model. Financial terms were not disclosed.   The Berlin-based research unit with around 400 workplaces comprises a fully operational team specialized in small molecule research. The research center reportedly comes with capabilities and capacities spanning the entire drug discovery value chain.   Bayer and Nuvisan “will cooperate closely in the coming years to build the new research center.” The transaction is expected to close mid of 2020 subject to successful completion of the consultation process with the employee representatives and the preparations for taking over the research activities.   

Recent Videos
Related Content